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Abstract
Background: Liver cancer stem cells (LCSCs) have been shown to express higher levels of microRNA-21 (miR-21).
Here, we examine the possible contributions of miR-21 to the phenotype of LCSCs in culture and in xenograft
tumors in nude mice.
Methods: The hepatocellular carcinoma cell line MHCC-97H was stably transformed with a retroviral vector to
establish cells overexpressing miR-21, while a cell line transformed with empty vector served as a negative control.
RT-PCR and Western blotting were used to evaluate the effects of miR-21 overexpression on the expression of
various LCSC markers, a Transwell assay was used to assess the effects on cell migration and invasion, and a
spheroid formation assay was used to examine the effects on clonogenesis. The effects of miR-21 overexpression
were also examined in tumors in nude mice.
Results: An MHCC-97H cell line was constructed that stably overexpresses miR-21 at 7.78 ± 1.51-fold higher levels than
the negative control cell line. Expression of the LCSC markers CD13, Ep-CAM, CD90, and OCT4 was significantly higher in
the miR-21-overexpressing cell line than in the negative control at both mRNA and protein levels. The overexpressing cell
line formed larger, tighter, and more numerous spheroids. Overexpression of miR-21 was associated with greater cell
migration and invasion. Tumors of overexpressing cells in nude mice had a significantly larger mean volume after 34 days
of growth (773.62 ± 163.46 mm3) than tumors of negative control cells (502.79 ± 33.94 mm3, p = 0.048), as well as greater
mean weight (0.422 ± 0.019 vs. 0.346 ± 0.006 g, p = 0.003).
Conclusions: Overexpression of miR-21 strengthens the phenotype of LCSCs, facilitating invasion, migration, and
tumorigenesis in hepatocellular carcinoma.
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Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignant tumors and a leading cause of cancer-
related deaths worldwide [1], making it a major health bur-
den [2]. Challenges in early HCC diagnosis mean that most
cases are detected too late to be curable. Surgical resection
remains the preferred treatment [3, 4], but postoperative
recurrence is high [5]. Therefore, understanding how HCC
recurs may allow the design of treatments or interventions
to reduce it.
Cancer stem cells (CSCs), also referred to as “side popula-
tions” because they are low-abundance subpopulations in
tumors, can initiate and sustain cell migration, invasion,
and treatment resistance. CSCs are responsible for poor
clinical outcome in tumor recurrence and metastasis [6, 7].
The malignancy of a tumor correlates directly with the pro-
portion of CSCs that it contains [8]. CSCs are not sensitive
to radio- or chemotherapy [9, 10], so they can evade treat-
ment and survive to cause recurrence. Liver cancer stem
cells (LCSCs), like other CSCs, are sub-populations of
tumor cells capable of unlimited proliferation, self-renewal,
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and differentiation [11, 12]. According to a hypothesis
advocated by many investigators [13], the chief culprit be-
hind HCC recurrence is LCSCs [6, 7, 13]. Inhibiting LCSC
proliferation and differentiation or even eradicating LCSCs
entirely may prove critical for reducing HCC recurrence
after hepatectomy [14, 15].
To move closer to this objective, researchers have devel-
oped methods to isolate LCSCs from HCC tumor tissue
and HCC cell lines such as MHCC-97H. Researchers have
screened for microRNAs (miRNAs) differentially expressed
between LCSCs and HCC cell lines. In many cancers in-
cluding HCC, miRNAs function as tumor suppressor genes
and as oncogenes to modulate tumor cell proliferation,
apoptosis, differentiation, and cell cycling [16]. In addition,
miRNAs regulate self-renewal and multi-differentiation to
determine stem cell fates [17–19]. In LCSCs, down- and
upregulation of certain miRNAs influence LCSC character-
istics such as clonogenicity and cell proliferation [19].
Recent studies have shown that microRNA-21 (miR-
21) is expressed at higher levels in various CSCs than in
the corresponding bulk tumor cells and that it influences
CSC behavior [20]. Inhibiting miR-21 expression in-
creases sensitivity to chemotherapy and inhibits colony-
forming ability. LCSCs, like other CSCs, have been
shown to express higher levels of miR-21 than bulk
HCC cells [21], and studies in which LCSCs were trans-
fected with an miR-21 mimic or inhibitor suggest that
miR-21 drives HCC recurrence and metastasis [22].
These studies were performed on isolated LCSCs, leav-
ing open the question of whether overexpression of
miR-21 strengthens stem cell-like characteristics in a he-
patocellular carcinoma cell line, which may provide an
excellent in vitro system for studying processes that
occur in postoperative HCC patients.
Therefore, in the present study, we generated an
MHCC-97H cell line stably transfected with a retroviral
vector encoding miR-21. We then analyzed in vitro the
effects of constitutive miR-21 overexpression on the ex-
pression of various LCSC markers (CD13, Ep-CAM,
CD90, OCT4) as well as on several LCSC functional
characteristics (spheroid formation, invasion, migration).
The cell surface markers CD13, Ep-CAM, and CD90 are
often used to enrich for LCSCs [23–26], while OCT4 is
a transcription factor essential for pluripotency and self-
renewal of embryonic stem cells [27–29]. To comple-
ment these in vitro studies, we examined the effects of




MHCC-97H and HEK 293 T cells were obtained from
the Liver Cancer Institute of Zhongshan Hospital, Fudan
University (Shanghai, China) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, USA) supple-
mented with 10 % fetal bovine serum (FBS; Gibco,
USA), 100 units/ml penicillin, and 100 mg/ml strepto-
mycin. Cultures were incubated at 37 °C in a humidified
atmosphere containing 5 % CO2.
Plasmid constructs
We cloned the miR-21 gene from 7702 liver cell gen-
omic DNA (kindly provided by the Department of
Immunology, Guangxi Medical University) using the
following primers, which we designed using the Primer
5.0 software (Premier Biosoft International, USA):
BamH1 forward primer, 5′-CGCGGATCCTTCTT
GCCGTTCTGTAAGTGTT-3′; and SalI reverse primer,
5′-AGACGTCGAC TTCAAAACCCACAATGCAGCT
TAG-3′. The primers were used in a polymerase chain
reaction (PCR) to amplify a 589-bp product, which was
cleaved with BamH1 and Sal1 and ligated into the ap-
propriate cloning sites of the pBABE-puro retroviral
vector (Cell Biolabs, USA). The resulting construct was
named pBABE-puro-pre-miR-21.
Retroviral particle production
HEK 293 T cells were plated in six-well plates and main-
tained for 24 h in DMEM with 10 % FBS. When cells
were 60–70 % confluent, they were transfected with 1 μg
of packaging plasmid PIK [30, 31] (kindly provided by
the Department of Immunology, Guangxi Medical Uni-
versity), empty pBABE-puro vector, or pBABE-puro-pre-
miR-21 using Lipofectamine 2000 (Invitrogen, USA) in
OPTI-MEM I medium (Invitrogen) according to the
manufacturer’s instructions. After the 5-h incubation,
the medium was replaced with DMEM containing 10 %
FBS without antibiotics. Cells were incubated for an-
other 48 h, and the medium containing retroviral parti-
cles was harvested, filtered through a 0.22-μm filter
(Corning, USA) into a Falcon tube, and stored at −80 °C.
Stable cell line construction
MHCC-97H cells were seeded into six-well plates and
allowed to grow to 70–80 % confluence. Then, the cells
were infected with retroviral particles lacking miR-21
(negative control) or containing miR-21 in the presence
of polybrene (8 μg/ml, Sigma-Aldrich, USA) and incu-
bated for 24 h at 37 °C. The culture medium enriched in
retroviral particles was harvested and used to infect
fresh plates of 70–80 % confluent MHCC-97H cells,
which were incubated for another 24 h. The medium
was replaced with DMEM containing 10 % FBS and
1 μg/ml puromycin (Sigma) without other antibiotics,
and cultures were incubated for 2 weeks. Medium was
replaced every 3 days. Finally, the medium was replaced
with DMEM containing 10 % FBS, 100 units/ml penicil-
lin, 100 mg/ml streptomycin, and 500 ng/ml puromycin,
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and cultures were incubated for 2 months. The medium
was replaced every 3 days.
Quantitative real-time reverse transcription-PCR (RT-PCR)
to measure expression of miR-21 and CSC marker genes
Total RNA was extracted from cells using Trizol (Invi-
trogen) according to the manufacturer’s protocol.
Primers for reverse transcription were the following:
miR-21, 5′-CTCAACTGGTGTCGTGGAGTCGGCAA
TTCAGTTGAGTCAACAT-3′; and U6, 5′-CTCGCTT
CGGCAGCACA-3′. The reverse transcription reaction
was carried out at 4 °C for 20 min, 16 °C for 30 min,
42 °C for 30 min, and 85 °C for 5 s, followed by a hold
at 4 °C.
Reverse transcription of CSC marker genes was car-
ried out using the PrimeScript® RT Kit (Takara Biotech-
nology, Dalian, China), followed by quantitative PCR in
a 7300 Real-Time PCR System (Applied Biosystems,
USA) using SYBR® Premix Ex Taq™ II (Takara Biotech-
nology). The primers used in these reactions are listed
in Table 1. Levels of miR-21 were normalized to levels
of U6, while levels of CSC marker mRNAs were nor-
malized to levels of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA. All results were
calculated using the 2[−ΔΔC(T)] method. All experi-
ments were performed in triplicates.
Western blot analysis
Total cell lysates were prepared from the negative con-
trol cell line and cell line stably transfected with miR-21,
fractionated on SDS-PAGE and transferred to PVDF
membranes (Millipore). After blocking the membranes
in phosphate-buffered saline (PBS) containing 0.1 %
Tween 20 (PBST) and 5 % non-fat dry milk for 2.5 h at
room temperature, the PVDF membranes were probed
at 4 °C overnight with rabbit antibodies (Abcam, UK)
against CD13 (1:2,000), Ep-CAM (1:2,000), CD90
(1:1,000), and OCT4 (1:2,000). Then, membranes were
washed with PBST three times and incubated for 2 h at
room temperature with horseradish peroxidase (HRP)-
conjugated secondary antibody (1:2,000; Abcam). After
washing the membranes three times with PBST, the pro-
teins were detected using enhanced chemiluminescence
(Thermo, USA) and quantified using ImageLab 5.0 (Bio-
Rad, USA). Protein levels were normalized to the
amount of GAPDH detected on the same blot. Repre-
sentative data from three independent experiments are
shown.
Spheroid formation assay
To measure spheroid formation by stable cell lines, nega-
tive control cells and cells stably transfected with miR-21
were mixed with serum-free DMEM/F12 medium con-
taining B27 supplement (1:50; Invitrogen), 20 ng/mL epi-
dermal growth factor (Invitrogen), and 20 ng/mL basic
fibroblast growth factor (Invitrogen) and plated in six-well
dishes (2000 cells per well). Cells were incubated for
14 days, and the medium was replaced every 3 days.
Spheroids were counted and photographed under a
microscope (Nikon, Tokyo, Japan). All experiments were
performed in triplicates.
Migration and invasion assays
Cell migration and invasion were analyzed using Trans-
well cell culture chambers with 8-μm pores (Corning,
USA). The upper chamber was coated with Matrigel
(Corning) for invasion assays, but not for migration assays.
Cells (105) were added to the upper chamber without FBS,
while lower chambers were immersed in medium contain-
ing 10 % FBS as a chemoattractant; the culture chambers
were then incubated for 24 h at 37 °C. Cells were removed
from the upper chamber using cotton swabs, and the fil-
ters were stained with methanol for 5 min at 37 °C, then
fixed with Giemsa’s solution (Solarbio, China) for 10 min
at 37 °C. Numbers of migrating and invasive cells were
counted in five randomly selected fields on each filter.
Representative data from three independent experiments
are shown.
Tumorigenicity in vivo
Animal studies were performed according to the Guide-
lines of Intramural Animal Use and were approved by
the Animal Ethics Committee of Guangxi Medical Uni-
versity. Negative control cells or cells stably transfected
with miR-21 (1 × 107) were suspended in a 1:1 (v/v) mix-
ture of 100 μl PBS and Matrigel (BD, USA) and injected
subcutaneously into both sides of five male BALB/C
Table 1 Primers used for reverse transcription and amplification
of genes related to liver cancer stem cells
Gene Primer sequence(5′→3′)














F forward, R reverse
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nude mice aged 5–6 weeks (Laboratory Animal Center,
Guangxi Medical University). Tumor length and width
were examined every 3–5 days in a specific pathogen-
free laboratory using a vernier caliper. At 34 days after
injection, nude mice were given an intraperitoneal injec-
tion of chloral hydrate, and then killed by cervical dis-
location. Tumors were weighed, and tumor volumes
were calculated using the equation: volume (mm3)
= (length × width2)/2.
Statistical analysis
Statistical analysis was performed using SPSS 19.0 (IBM,
USA). Data were presented as mean ± standard devi-
ation, and inter-group differences were assessed for sig-
nificance using Student’s t test. All statistics should be
two-tailed, and the threshold of significance was defined
to be p < 0.05.
Results
An HCC cell line stably overexpressing miR-21
The analysis of PCR reactions on 1.0 % agarose showed
the desired 589-bp miR-21 amplicon, which was digested
with BamHI and SalI for insertion into the retroviral
vector. The expression construct pBABE-puro-pre-miR-
21 was transformed into E. coli DH5. Plasmid DNA was
isolated from a panel of transformants and digested with
BamHI/SalI to screen for the 589-bp insert. The result-
ing pBABE-puro-pre-miR-21 was used to create an
MHCC-97H cell line stably overexpressing miR-21
(Fig. 1). RT-PCR analysis showed that miR-21 expression
was 7.78 ± 1.51-fold higher in the miR-21-transfected
cultures than in the negative control cultures (p < 0.05).
miR-21 increased the expression of LCSC markers
Cells stably overexpressing miR-21 contained approxi-
mately twofold more mRNA encoding four LCSC
markers than in the negative control cells: for CD13, the
difference was 2.07 ± 0.10-fold (p = 0.004); Ep-CAM,
2.23 ± 0.13 (p = 0.006); CD90, 2.01 ± 0.10 (p = 0.005); and
OCT4, 1.97 ± 0.12 (p = 0.008; Fig. 2a). Expression of the
four corresponding proteins was also significantly higher
in miR-21-overexpressing cells (p < 0.05; Fig. 2b). These
results indicate that miR-21 overexpression strengthened
the LCSC phenotype.
miR-21 increased clonogenicity
Negative control cells and cells stably overexpressing
miR-21 formed loose aggregates that eventually coa-
lesced into compact, tight, rounded spheres that grew
over the 14-day incubation. Sphere morphology was ana-
lyzed in detail using light microscopy, which showed
that miR-21-overexpressing cells formed tighter, larger,
more numerous, and more confluent spheres (Fig. 3).
These results indicated that higher expression of LCSC
surface markers correlated with greater sphere-forming
ability.
miR-21 promoted migration and invasion
In Transwell assays, miR-21-overexpressing cells showed
greater migration and invasion ability than the negative
control cells. The number of migrating cells measured in
randomly selected fields of the Transwell culture insert
was significantly higher with the miR-21-overexpressing
cultures than the negative control cultures (210.3 ± 5.8
vs. 104.8 ± 6.5, p < 0.001), and the relative number of
cells that invaded through the extracellular matrix
Fig. 1 An MHCC-97H cell line stably overexpressing miR-21 was selected
and cultured in the presence of puromycin (magnification, ×200). a, b
Negative control (NC) cultures and cultures stably transfected with miR-
21 were mock-transfected in the absence of retroviral particles. c, d
Transfected cells were grown for 2 weeks in DMEM containing 1 μg/ml
puromycin without other antibiotics. e, f The two cell lines were cultured
for 2 months in DMEM containing 500 ng/ml puromycin without other
antibiotics. g Relative expression of miR-21 was determined by RT-PCR.
*p< 0.05, compared with NC
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coating was significantly higher for the miR-21-
overexpressing cultures (107.3 ± 2.3) than for the nega-
tive control cultures (56.7 ± 2.5, p < 0.001; Fig. 4).
miR-21 accelerated tumor growth in BALB/C nude mice
BALB/C nude mice were inoculated with negative con-
trol cells or cells stably transfected with miR-21, and tu-
mors were allowed to grow. Tumors were visible after
5 days in both groups of mice, but tumors from cells
overexpressing miR-21 grew significantly faster (Fig. 5b).
On day 28 after inoculation, two mice died, and post-
mortem dissection showed them to have pulmonary me-
tastases. Mean tumor volume at the end of the 34-day
observation period was 773.62 ± 163.46 mm3 in the miR-
21 group and 502.79 ± 33.94 mm3 in the negative control
group (p = 0.048), while the corresponding mean weights
were 0.422 ± 0.019 g and 0.346 ± 0.006 g (p = 0.003,
Table 2 and Fig. 5c), respectively. Tumor pathology was
verified by histopathology.
Discussion
LCSCs are thought to arise from hepatocyte de-
differentiation or transformation from hepatic progeni-
tor cells, and many investigators believe that LCSCs gen-
erate and maintain HCC and drive postoperative
recurrence [15, 32, 33]. This implies that inhibiting and
Fig. 2 Expression of LCSC markers in an MHCC-97H cell line stably
overexpressing miR-21 cells. a The levels of the corresponding
mRNAs were determined using RT-PCR. b The levels of CD13, Ep-
CAM, CD90, and OCT4 protein in the miR-21-overexpressing cell line
and corresponding negative control (NC) line were measured using
Western blotting. *p < 0.05, compared with NC
Fig. 3 Overexpression of miR-21 promotes spheroid formation. a, b
MHCC-97H cell line stably overexpressing miR-21 and the corre-
sponding negative control (NC) cell line were induced to form
spheroids for 14 days. The miR-21-overexpressing cell line formed
larger, tighter, and more numerous spheroids
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eliminating LCSCs may be key to reducing recurrence
[34, 35]. Here, we confirm and extend previous work in
isolated LCSCs by showing that overexpression of miR-
21 in the HCC cell line MHCC-97H directly affects nu-
merous functional characteristics of LCSCs, providing
mechanistic insight into the events that may drive HCC
recurrence and suggesting a potential therapeutic target.
Ep-CAM and CD90 are widely regarded as LCSC
markers, and higher expression of these markers has
been linked to greater risk of recurrence and shorter sur-
vival time in HCC [23, 24]. We found that miR-21 over-
expression was associated with increases in expression
of these markers and of the LCSC markers CD13 and
OCT4. Previous work showed that miR-21 can promote
tumor spread by upregulating the expression of phos-
phatase and tensin homolog (PTEN), programmed cell
death 4 (PDCD4) protein, and reversion-inducing
cysteine-rich protein with Kazal motifs (RECK) [22]. Fu-
ture studies should aim to determine the full range of
target genes affected by miR-21, since this may help clar-
ify the complex literature on risk factors of HCC
recurrence.
CD13, which helps pause LCSCs in G1/G0 phase of
the cell cycle [25], has already proven a useful drug tar-
get: the combination of a CD13 inhibitor with the geno-
toxin fluorouracil (5-FU) led to significantly smaller
tumor size than either drug on its own in a mouse xeno-
graft tumor model [26]. CD13 is special among LCSC
markers because its level changes during differentiation
of LCSCs in culture [36]: upregulation of CD13 is associ-
ated with the epithelial-mesenchymal transition and with
a reduction in apoptosis. It is also associated with the
Fig. 4 Overexpression of miR-21 promotes cell migration and invasion. a-d Transwell migration and Matrigel invasion assays were carried out
using MHCC-97H cells stably overexpressing miR-21 or the corresponding negative control (NC) cells. e, f Numbers of migrating and invading
cells counted in five fields randomly selected on the Transwell culture insert. *p < 0.001, compared with NC
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resistance of LCSCs to chemotherapy and more robust
survival [37]. OCT4 plays a pivotal role in maintaining
the multidirectional differentiation and self-renewal
properties of embryonic stem cells [27–29]. OCT4 is
highly expressed by cells highly enriched for CD90- and
CD133-positive LCSCs, and its expression is tightly as-
sociated with chemotherapy resistance [38]. Coexpres-
sion of OCT4 and another “stem-ness” marker, Nanog,
by HCC cells is associated with aggressive tumor behav-
ior and worse clinical outcome [28]. OCT4 can promote
CSC-like traits as well as the epithelial-mesenchymal
transition in HCC cells; it exerts these effects by regulat-
ing the Stat3/Snail pathway [39]. Future work should
examine whether OCT4 may be a reasonable therapeutic
target for preventing HCC recurrence.
How miR-21 may promote the behavior of LCSCs, or
of CSCs in general, remains unclear. Some mechanisms
have been proposed [40]. One is that miR-21 acts within
the tumor progenitor cells to modulate their self-
renewal. Another is that miR-21 in non-progenitor tissue
triggers tumor cell differentiation, leading to CSC pro-
duction. A third is that miR-21 in non-progenitor cells
produces growth factors that benefit CSCs.
Our observation that miR-21 overexpression increases
the ability of MHCC-97H cells to invade and metastasize
echoes a report that transfecting SMMC-7721 cells with
an miR-21 analog markedly enhanced their invasion and
metastasis abilities. Indeed, inhibiting miR-21 in MHCC-
97H cells reduced these abilities [41]. Similarly, silencing
trans-expressed miR-21 in isolated LCSCs reduced their
migration and invasion [22].
Our observation that miR-21 overexpression leads to
faster tumor growth in a nude mouse xenograft model is
consistent with a report that inhibiting miR-21 in pan-
creatic CSCs substantially decreased the growth of pan-
creatic tumor xenografts [42]. In another study,
colorectal cancer cells were stably transfected with miR-
21 plasmid and subcutaneously injected into female
SCID mice [43]. At 6 weeks after injection, tumors were
larger in mice injected with cells stably transfected with
miR-21 than in mice injected with the corresponding
empty vector. That work further showed that miR-21
overexpression can induce the appearance of colorectal
CSCs.
Conclusions
The results of the present study suggest that miR-21
overexpression can upregulate CD13, Ep-CAM, CD90,
and OCT4 expression. In addition, miR-21 strengthens
LCSC characteristics, including spheroid formation, in-
vasion, and migration. CSC marker expression may
regulate the expression and activity of miR-21, thereby
reinforcing the stem cell phenotype.
Fig. 5 Overexpression of miR-21 promotes the growth of subcutane-
ous xenograft tumors in nude mice. a Representative xenograft tu-
mors grown for 34 days using MHCC-97H cells stably overexpressing
miR-21 or the corresponding negative control (NC) cells. b The
tumor volume and c tumor weight were compared between the
two stable cell lines. *p < 0.05, compared with NC
Table 2 Subcutaneous xenograft tumor weight at 34 days after
tumor cell injection
Cell line Weight, g (mean ± SD) P
Negative control 0.346 ± 0.006 0.003
miR-21 0.422 ± 0.019
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